Fig. 2: The intraretinal expression pattern of mCherry-BCLXL following AAV2-Pgk-mCherry-BclXL transduction.
From: BCLXL gene therapy moderates neuropathology in the DBA/2J mouse model of inherited glaucoma
A A map showing the plasmid that was packaged into AAV2-Pgk-mCherry-BclXL. B A retinal whole-mount preparation, 4 weeks after intravitreal injection, showing wide-spread expression of the transgene across the retina. Scale bar = 450 µm. C–F Co-localization of BRN3A-positive cells that were transduced by AAV2-Pgk-mCherry-BclXL (arrows). An asterisk labels a transgene expressing cell that is BRN3A negative but appears to project a labeled axon into the nerve fiber layer. Only the ganglion cell layer (GCL) is shown. Scale bar = 20 µm. G Graph showing the percentages of total cells in the GCL and BRN3A-positive cells that expressed the mCherry-BCLXL transgene (mean ± standard deviation).
